Background Survivors of childhood cancer treated with CNS-directed therapy may be at-risk for poor healthcare utilization Azelnidipine due to neurocognitive deficits. neurocognitive function and health screenings. Established predictors of healthcare utilization were included as covariates. Odds ratios (OR) or prevalence ratios (PR) and 95% confidence intervals (CIs) were calculated for Azelnidipine variables maintained in the… Continue reading Background Survivors of childhood cancer treated with CNS-directed therapy may be